A trial fibrillation (AF) is the most common sustained arrhythmia in clinical practice. Although antiarrhythmic agents promote sinus rhythm maintenance, they can cause potentially serious proarrhythmia. 1 A potential new approach to AF therapy is to target the underlying substrate. 2 We recently found that dogs with ventricular tachypacing (VTP)-induced congestive heart failure (CHF) have a substrate for AF maintenance, 3 with interstitial fibrosis that resembles atrial pathology in many patients with AF. 4 The renin-angiotensin system is involved in myocardial fibrosis in hypertensive heart disease, 5 CHF, 6 myocardial infarction, 7 and cardiomyopathy. 8 Angiotensin II (Ang II) stimulates collagen synthesis in rat cardiac fibroblasts. 9, 10 Mitogen-activated protein kinases (MAPKs) are important mediators of Ang II effects on tissue structure. 11, 12 The 3 best-characterized MAPK subfamilies are extracellular signal-regulated protein kinase (ERK), c-Jun N-terminal kinase (JNK), and p38-MAPKs. 12, 13 Recent studies showed ERK activation 14 and angiotensin receptor changes 15 in patients with AF. We speculated that Ang II and MAPK activation might be involved in AFpromoting atrial structural remodeling. We therefore designed this study to determine (1) the changes in atrial Ang II and MAPKs during the development of VTP-induced CHF in dogs, (2) the effect of ACE inhibition on atrial Ang II and MAPKs, and (3) the impact of ACE inhibition on AF substrate development.
Methods Enalapril Effects on the CHF-Induced AF Substrate
The following groups of mongrel dogs (25 to 33 kg) were studied: controls (nϭ7), placebo-VTP group (nϭ10), and enalapril-VTP group (nϭ10). The placebo and enalapril groups were subjected to VTP 3 for 5 weeks (240 bpm for 3 weeks, 220 bpm 2 weeks) and given either placebo or enalapril (2 mg · kg Ϫ1 · d Ϫ1 , Merck Frosst) during VTP. Investigators were blinded to treatment assignment until all analyses were completed. Five additional dogs were subjected to the same protocol with oral hydralazine (50 mg twice daily) and isosorbide mononitrate (30 mg/d) given throughout the VTP period. Heart failure was established by lethargy, loss of appetite, dyspnea, peripheral edema, and/or ascites associated with appropriate hemodynamic abnormalities. On study days, dogs were anesthetized with morphine (2 mg/kg SC) and ␣-chloralose (120 mg/kg IV, 29.25 mg · kg Ϫ1 · h Ϫ1 ) and ventilated. Body temperature was maintained at 37°C, and a femoral artery and femoral veins were cannulated for pressure monitoring and drug administration. A median sternotomy was performed, and bipolar Teflon-coated stainless steel electrodes were hooked into the atrial appendages. A programmable stimulator was used to deliver 2-ms twice-threshold pulses. Atrial electrograms were recorded to confirm that atrial rate was not affected by ventricular pacing. The implanted pacemaker was then deactivated.
Electrophysiological Study
Stimulation and recording were performed and atrial activation was mapped with 248 epicardial electrodes as previously described. 3 The effective refractory period (longest S 1 S 2 failing to capture) was measured at left atrial (LA) and right atrial (RA) appendages, with 15 basic (S 1 ) stimuli followed by a premature (S 2 ) stimulus, with S 1 S 2 decreasing by 5-ms decrements. The mean of 3 effective refractory period measurements was used for analysis. Conduction velocity was measured, as previously described, in the RA and LA free wall after 2 minutes at each basic cycle length. 3 Spatial inhomogeneities in conduction were evaluated by phase analysis as previously reported. 3 The P (difference between 5th and 95th percentiles of the phase-difference distribution) indicates absolute heterogeneity. The variation coefficient (P 5-95 /P 50 ) is an index of conduction heterogeneity independent of conduction velocity. 3 AF was induced by atrial burst pacing (10 Hz, 1 to 5 seconds). AF Ͼ20 minutes requiring electrical cardioversion for termination was considered persistent. To estimate mean AF duration, AF was induced 10 times for AF duration Ͻ10 minutes and 5 times for AF of 10 to 20 minutes. If persistent AF was induced twice, no further AF inductions were performed. A 30-minute rest period was allowed after cardioversion.
Microscopic Examination
Animals were euthanized by ␣-chloralose overdose. Atria were immersed in 10% neutral buffered formalin for 24 hours. Samples were obtained from Bachmann's bundle, the appendages, the LA posterior and inferior walls, the crista terminalis, and the RA free wall. From each zone, tissue blocks were collected along the longitudinal and transverse planes. Sections (5-m thickness) were cut at room temperature and stained with Masson's trichrome, and fibrous tissue content was measured by quantitative image analysis as previously described. 4 
Studies of Changes in Tissue Ang II and MAPK Expression
Sixty additional dogs were divided into 5 groups (12 per group): controls (no pacing) and groups subjected to 1 day and 1, 2, and 5 weeks of VTP as described above. In addition, we examined the effects of enalapril in 18 other dogs (3 groups, 6 per group). Enalapril (2 mg · kg Ϫ1 · d Ϫ1 PO) was begun 2 days before pacing and continued throughout 1-day, 1-week, or 5-week pacing intervals. Because in vivo electrophysiological studies, including mapping, affected protein analyses, no in vivo studies were performed in dogs used for biochemical analyses.
At the conclusion of the pacing period, dogs were euthanized with an overdose of pentobarbital, and the LA was removed, frozen in liquid nitrogen, and stored at Ϫ80°C. Expression of MAPKs was quantified as previously described. 14, 16 LA tissue (Ϸ3 g) was pulverized in liquid nitrogen and suspended in 3 mL ice-cold lysis buffer (mmol/L: Tris-HCl 50, ␤-glycerophosphate 20, NaF 20, EDTA 5, EGTA 10, Na 3 VO 4 1, benzamidine 10, PMSF 0.5, and dithiothreitol 5, plus 10 g/mL leupeptin, 1 mol/L microcystin LR, and 1% [vol/vol] Triton X-100). The suspension was incubated on ice and centrifuged (100 000g, 15 minutes, 4°C), and the soluble fraction was stored at Ϫ80°C. Protein concentration was determined by Bradford assay.
Protein extracts (40 g) were denatured in Laemmli buffer and electrophoresed on 8% SDS-polyacrylamide gels. Proteins were transferred to Immobilon-P polyvinylidine difluoride membranes, blocked with 5% nonfat dry milk in Tris-buffered saline (TBS), and incubated overnight in primary-antibody solutions. After 5 washes in 0.1% Tween 80 -TBS (TTBS), membranes were reblocked in 1% nonfat dry milk in TTBS for 10 minutes and then incubated with horseradish peroxidase-conjugated primary antibodies in 5% nonfat dry milk in TTBS for 60 minutes, followed by 4 additional washes in TTBS. Antibody detection was performed with Western blot chemiluminescence reagent plus. Band densities were quantified by densitometry (Quality One software) standardized to average control values. Each set of gels contained 1 control sample and samples for 1-day and 1-, 2-, and 5-week tachypacing (time-course studies) and control, 1-day, and 1-, 2-, and 5-week tachypacing (without drug) plus 1-day and 1-and 5-week tachypacing with enalapril (enalapril studies).
The following primary antibodies were used for immunodetection: rabbit anti-P44/P42 polyclonal IgG (phosphorylated and total ERK), rabbit anti-P38 polyclonal IgG (phosphorylated and total p38), rabbit anti-JNK polyclonal IgG (total JNK), mouse anti-JNK monoclonal IgG (phosphorylated JNK), and goat polyclonal anti-Ang II type 1 (AT 1 ) and type 2 (AT 2 ) receptor. The anti-phosphorylated MAPK antibodies detect only kinases catalytically activated by threonine or tyrosine phosphorylation. Tissue Ang II concentration was measured by ELISA. 17 Protein samples (500 g) were analyzed in a microtiter plate with an anti-Ang II antibody (Peninsula) and biotinylated Ang II. The microplate was washed 5 times with TTBS and treated with streptavidin-horseradish peroxidase. The color reaction was developed with 100 L tetramethylbenzidine substrate and terminated with 2N HCl. Absorbance at 450 nm was recorded, and concentration was calculated from a standard curve generated for each experiment.
Statistical Analysis
Multiple group means were compared by ANOVA, followed by Bonferroni-corrected t tests. Wilcoxon's signed-rank test was used to compare AF durations between groups. Results are meanϮSEM, and a 2-tailed value of PϽ0.05 was considered statistically significant.
Results

Changes in Hemodynamic Indices
Overall group characteristics and hemodynamic data are provided in Table 1 . Left ventricular diastolic and atrial pressures increased in 5-week VTP dogs. The enalapriltreated VTP dogs demonstrated improved hemodynamics compared with placebo-treated VTP animals.
VTP Increases Ang II and MAPK Expression
Atrial Ang II concentration increased almost 3-fold within 1 day of VTP and remained elevated thereafter ( Figure 1A ). VTP significantly increased the expression of all MAPKs. Phosphorylated ERK increased within 1 day of VTP ( Figure  1B ), peaked within a week, and declined thereafter. Phosphorylated JNK ( Figure 1C ) and p38 ( Figure 1D ) peaked within 24 hours of VTP and then declined. Changes in total ERK qualitatively paralleled the phosphorylated form but were smaller, and significant increases were noted only at 1 week. In contrast, changes in total JNK and p38 quantitatively paralleled the phosphorylated forms. Increases in phosphorylated ERK correlated with tissue Ang II concen-tration (rϭ0.56, nϭ60, PϽ0.0001), whereas changes in JNK and p38 did not (rϭ0.19 and 0.12, respectively, PϭNS).
Effects of Long-Term Enalapril on Ang II and MAPKs
Enalapril reduced tissue Ang II concentrations ( Figure 2A ) and significantly reduced phosphorylated ERK expression ( Figure 2C ). Enalapril-induced changes in total ERK were small and statistically nonsignificant ( Figure 2D) . When values of phosphorylated ERK with and without enalapril therapy were related to values of Ang II, there was a clear correlation (rϭ0.58, nϭ84, PϽ0.0001, Figure 2B ). Enalapril had no effect on pacing-induced increases in phosphorylated ( Figure 3A) or total ( Figure 3B ) JNK or on phosphorylated ( Figure 3C ) or total ( Figure 3D ) p38.
VTP increased AT 1 receptor expression, which peaked at 340Ϯ18% of control at 24 hours and then returned toward control values (133Ϯ8% at 5 weeks). AT 2 receptor expression 
Effects of Enalapril on the AF Substrate
In unpaced dogs ( Figure 4A ), atria appeared grossly normal. In 5-week tachypaced dogs ( Figure 4B ), bundles of myofibers were separated by thick layers of fibrous tissue. In enalapriltreated dogs ( Figure 4C ), interstitial fibrosis appeared attenuated. Overall, the percentage of fibrous tissue was increased Ϸ10-fold in placebo dogs, with fibrosis significantly attenuated by enalapril ( Figure 4D ). Figure 5 shows isochronal activation maps (A), phase maps (B), and phase-delay histograms (C) during 1:1 pacing (basic cycle length 300 ms) at the RA appendage from representative dogs in the control, VTP alone, and VTP with enalapril groups. VTP increased the heterogeneity of conduction in the example shown, an effect attenuated by enalapril therapy. Figure 6 provides mean data for the phase-delay analysis of the histogram data shown in Figure 5C . VTP did not affect the median phase time (P 50 ). Absolute heterogeneity (P ) and the heterogeneity index (P 5-95 /P 50 ) were increased significantly in placebo dogs, effects that were attenuated by enalapril.
VTP increased AF duration from 17Ϯ8 to 651Ϯ164 seconds (PϽ0.01, Table 2 ). Mean AF duration in enalapril-VTP dogs was reduced significantly, to 219Ϯ75 seconds (PϽ0.05 versus VTP only). 
Hydralazine/Isosorbide Dogs
VTP dogs treated with hydralazine/isosorbide had left ventricular diastolic and atrial pressures similar to those of enalapril dogs and lower than those of VTP-only dogs (Table  1) . Despite this hemodynamic improvement, mean AF duration was similar to VTP-only dogs, and 4 of 5 dogs (80%) had at least one episode of persistent AF. Hydralazine/isosorbide did not affect CHF-induced fibrosis ( Figure 4D ), which averaged 11.7Ϯ1.5% in hydralazine/isosorbide-VTP dogs (PϭNS versus VTP only).
Discussion
We found that VTP increased atrial Ang II concentration and phosphorylated MAPK. Enalapril attenuated VTP-induced changes in Ang II and ERK, without affecting JNK and p38, and reduced atrial arrhythmogenic remodeling (fibrosis, conduction abnormalities, and AF duration changes). Vasodilator therapy with hydralazine/isosorbide did not affect VTPinduced atrial fibrosis or AF promotion.
Atrial Structural Remodeling, Signal Transduction Systems, and AF
Interstitial fibrosis is common in patients with AF. 4 The likelihood of AF increases with increasing extent of fibrosis. 18 Prominent fibrosis is also a feature in animal models of AF associated with heart disease. 3, 19, 20 Electrically maintained AF in normal goats causes cellular ultrastructural remodeling, without apoptotic or fibrotic changes. 21 In dogs with atrial remodeling caused by atrial tachypacing (640 bpm) and mitral regurgitation, a combination of electrical and structural remodeling increases vulnerability to AF induction. 22 Little is known about the potential signal transduction systems leading to the structural remodeling associated with AF. Goette et al 14 reported that AT 1 receptors are downregulated and AT 2 receptors upregulated in patients with AF. The same group observed increased expression of ACE and ERK in atria of AF patients. 15 Our findings are consistent with an important role for Ang II in mediating VTP-induced increased ERK phosphorylation and arrhythmogenic structural remodeling. Ang II activates ERK in cardiac fibroblasts by a tyrosine kinase-dependent mechanism. 23 Mechanical stretch of cardiomyocytes activates both ERK and JNK, but only ERK activation depends on Ang II production. 24 ERK activation is particularly important in the stimulation of fibroblast proliferation. 25 Our results suggest that the changes in atrial angiotensin and ERK systems noted by Goette et al 14, 15 in AF may be mechanistically related to AF-promoting structural remodeling. 
Role of the Renin-Angiotensin System and Related Pathways in Cardiac Fibrosis
Exposure of cultured fibroblasts to Ang II or aldosterone promotes collagen synthesis; in addition, Ang II reduces collagenase activity. 9 Activation of the renin-angiotensin system leads to cardiac fibrosis in a variety of pathological conditions. In experimental hypertension, Ang II and aldosterone cause ventricular fibrosis that can be dissociated from hemodynamic load. 5, 6 Inhibition of ACE 26 or AT 1 receptor blockade 27 prevents collagen accumulation in the noninfarcted myocardium after acute myocardial infarction in rats. AT 1 receptor inhibition attenuates fibrotic changes in isoproterenol-induced heart failure. 28 Overexpression of AT 1 receptors in transgenic mice results in cardiac hypertrophy, interstitial fibrosis, and death due to progressive heart failure. 29 The present study shows that inhibition of Ang II production reduces atrial fibrosis and arrhythmogenic remodeling in dogs with CHF.
The MAPKs ERK, JNK, and p38 can all be activated by Ang II. 11, 30 ERK is most typically stimulated via G proteincoupled receptors like the AT 1 receptor. 30 ERK is important in cell growth, proliferation, and differentiation 31 and plays a key role in the response of fibroblasts to growth signals. 25 We found differences in the expression pattern of the MAPKs studied. Changes in phosphorylated JNK and p38 were quantitatively similar to those of total expression ( Figures 1C  and 1D ), consistent with an increase in JNK and p38 protein as the primary alteration caused by VTP. Conversely, increases in phosphorylated ERK were considerably greater than those of total ERK ( Figure 1B ), pointing to increased ERK phosphorylation as the primary mechanism for atrial ERK activation.
Novel Aspects and Potential Significance
This is the first study of the role of Ang II and MAPK expression changes in an experimental model of AFpromoting atrial structural remodeling. Our findings indicate that enalapril reduces atrial fibrosis, conduction abnormalities, and AF promotion while reducing atrial Ang II concentrations and ERK activation. AF has traditionally been treated with membrane-active antiarrhythmic drugs that can prevent AF at the price of potential mortality-enhancing proarrhythmic actions. 1,2 An alternative approach is to attack the arrhythmia substrate. In the present study, ACE inhibition attenuated CHF-induced atrial fibrosis that causes local conduction abnormalities, which help to sustain AF. 3 Our findings provide mechanistic support for clinical observations pointing to efficacy against AF of ACE inhibitors in patients with CHF 32 or left ventricular dysfunction after acute myocardial infarction. 33 It remains to be determined whether interfering with the renin-angiotensin system can reverse established arrhythmogenic atrial structural remodeling. Lisinopril reverses ventricular fibrosis in patients with hypertensive heart disease, 34 but captopril failed to reverse tissue fibrosis after heart failure was established in spontaneously hypertensive rats. 35 It also remains to be determined whether ACE inhibition can prevent atrial arrhythmogenic remodeling associated with conditions other than CHF that promote atrial fibrosis and AF, such as hypertension and senescence.
Potential Limitations
Although enalapril significantly attenuated a range of effects of CHF, the protection conferred was incomplete: atrial fibrosis still occurred, and AF duration was greater in enalapril-treated dogs than in controls. Incomplete protection may have been because enalapril attenuated, but did not eliminate, the tissue Ang II increase associated with CHF ( Figure 2A ). In addition, enalapril did not prevent activation of JNK and p38-MAPK. Furthermore, other profibrotic signal transduction elements may have been activated by CHF and not affected by enalapril. Further work is necessary to determine whether other agents (such as other ACE inhibitors, AT 1 receptor antagonists, ␤-adrenoceptor blockers, or aldosterone antagonists) are effective in preventing atrial structural remodeling and to define the mechanisms involved.
Conclusions
CHF increases atrial Ang II concentrations and MAPK expression. Enalapril reduces VTP-induced Ang II concentration, ERK activation, atrial fibrosis, conduction abnormalities, and AF promotion. The inhibition of structural remodeling may be a promising new approach in the treatment of AF. 
